A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement. / Eslam, Mohammed; Newsome, Philip N.; Sarin, Shiv K.; Anstee, Quentin M.; Targher, Giovanni; Romero-Gomez, Manuel; Zelber-Sagi, Shira; Wai-Sun Wong, Vincent; Dufour, Jean François; Schattenberg, Jörn M.; Kawaguchi, Takumi; Arrese, Marco; Valenti, Luca; Shiha, Gamal; Tiribelli, Claudio; Yki-Järvinen, Hannele; Fan, Jian Gao; Grønbæk, Henning; Yilmaz, Yusuf; Cortez-Pinto, Helena; Oliveira, Claudia P.; Bedossa, Pierre; Adams, Leon A.; Zheng, Ming Hua; Fouad, Yasser; Chan, Wah Kheong; Mendez-Sanchez, Nahum; Ahn, Sang Hoon; Castera, Laurent; Bugianesi, Elisabetta; Ratziu, Vlad; George, Jacob.

I: Journal of Hepatology, Bind 73, Nr. 1, 2020, s. 202-209.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, Zelber-Sagi, S, Wai-Sun Wong, V, Dufour, JF, Schattenberg, JM, Kawaguchi, T, Arrese, M, Valenti, L, Shiha, G, Tiribelli, C, Yki-Järvinen, H, Fan, JG, Grønbæk, H, Yilmaz, Y, Cortez-Pinto, H, Oliveira, CP, Bedossa, P, Adams, LA, Zheng, MH, Fouad, Y, Chan, WK, Mendez-Sanchez, N, Ahn, SH, Castera, L, Bugianesi, E, Ratziu, V & George, J 2020, 'A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement', Journal of Hepatology, bind 73, nr. 1, s. 202-209. https://doi.org/10.1016/j.jhep.2020.03.039

APA

Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J. F., Schattenberg, J. M., Kawaguchi, T., Arrese, M., Valenti, L., Shiha, G., Tiribelli, C., Yki-Järvinen, H., Fan, J. G., Grønbæk, H., Yilmaz, Y., ... George, J. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73(1), 202-209. https://doi.org/10.1016/j.jhep.2020.03.039

CBE

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. 2020. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology. 73(1):202-209. https://doi.org/10.1016/j.jhep.2020.03.039

MLA

Vancouver

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M o.a. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology. 2020;73(1):202-209. https://doi.org/10.1016/j.jhep.2020.03.039

Author

Eslam, Mohammed ; Newsome, Philip N. ; Sarin, Shiv K. ; Anstee, Quentin M. ; Targher, Giovanni ; Romero-Gomez, Manuel ; Zelber-Sagi, Shira ; Wai-Sun Wong, Vincent ; Dufour, Jean François ; Schattenberg, Jörn M. ; Kawaguchi, Takumi ; Arrese, Marco ; Valenti, Luca ; Shiha, Gamal ; Tiribelli, Claudio ; Yki-Järvinen, Hannele ; Fan, Jian Gao ; Grønbæk, Henning ; Yilmaz, Yusuf ; Cortez-Pinto, Helena ; Oliveira, Claudia P. ; Bedossa, Pierre ; Adams, Leon A. ; Zheng, Ming Hua ; Fouad, Yasser ; Chan, Wah Kheong ; Mendez-Sanchez, Nahum ; Ahn, Sang Hoon ; Castera, Laurent ; Bugianesi, Elisabetta ; Ratziu, Vlad ; George, Jacob. / A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement. I: Journal of Hepatology. 2020 ; Bind 73, Nr. 1. s. 202-209.

Bibtex

@article{0dcc15245cb9489496b9f638825d9fb3,
title = "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement",
abstract = "The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.",
keywords = "Cirrhosis, Diabetes, Diagnostic criteria, MAFLD, Metabolic, NAFLD, Obesity, Steatohepatitis",
author = "Mohammed Eslam and Newsome, {Philip N.} and Sarin, {Shiv K.} and Anstee, {Quentin M.} and Giovanni Targher and Manuel Romero-Gomez and Shira Zelber-Sagi and {Wai-Sun Wong}, Vincent and Dufour, {Jean Fran{\c c}ois} and Schattenberg, {J{\"o}rn M.} and Takumi Kawaguchi and Marco Arrese and Luca Valenti and Gamal Shiha and Claudio Tiribelli and Hannele Yki-J{\"a}rvinen and Fan, {Jian Gao} and Henning Gr{\o}nb{\ae}k and Yusuf Yilmaz and Helena Cortez-Pinto and Oliveira, {Claudia P.} and Pierre Bedossa and Adams, {Leon A.} and Zheng, {Ming Hua} and Yasser Fouad and Chan, {Wah Kheong} and Nahum Mendez-Sanchez and Ahn, {Sang Hoon} and Laurent Castera and Elisabetta Bugianesi and Vlad Ratziu and Jacob George",
year = "2020",
doi = "10.1016/j.jhep.2020.03.039",
language = "English",
volume = "73",
pages = "202--209",
journal = "Journal of Hepatology. Supplement",
issn = "0169-5185",
publisher = "Elsevier BV",
number = "1",

}

RIS

TY - JOUR

T1 - A new definition for metabolic dysfunction-associated fatty liver disease

T2 - An international expert consensus statement

AU - Eslam, Mohammed

AU - Newsome, Philip N.

AU - Sarin, Shiv K.

AU - Anstee, Quentin M.

AU - Targher, Giovanni

AU - Romero-Gomez, Manuel

AU - Zelber-Sagi, Shira

AU - Wai-Sun Wong, Vincent

AU - Dufour, Jean François

AU - Schattenberg, Jörn M.

AU - Kawaguchi, Takumi

AU - Arrese, Marco

AU - Valenti, Luca

AU - Shiha, Gamal

AU - Tiribelli, Claudio

AU - Yki-Järvinen, Hannele

AU - Fan, Jian Gao

AU - Grønbæk, Henning

AU - Yilmaz, Yusuf

AU - Cortez-Pinto, Helena

AU - Oliveira, Claudia P.

AU - Bedossa, Pierre

AU - Adams, Leon A.

AU - Zheng, Ming Hua

AU - Fouad, Yasser

AU - Chan, Wah Kheong

AU - Mendez-Sanchez, Nahum

AU - Ahn, Sang Hoon

AU - Castera, Laurent

AU - Bugianesi, Elisabetta

AU - Ratziu, Vlad

AU - George, Jacob

PY - 2020

Y1 - 2020

N2 - The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.

AB - The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.

KW - Cirrhosis

KW - Diabetes

KW - Diagnostic criteria

KW - MAFLD

KW - Metabolic

KW - NAFLD

KW - Obesity

KW - Steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85083788691&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2020.03.039

DO - 10.1016/j.jhep.2020.03.039

M3 - Review

C2 - 32278004

AN - SCOPUS:85083788691

VL - 73

SP - 202

EP - 209

JO - Journal of Hepatology. Supplement

JF - Journal of Hepatology. Supplement

SN - 0169-5185

IS - 1

ER -